New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
06:36 EDTAERIAerie Pharmaceuticals reports positive results from AR-13324 study
Aerie Pharmaceuticals announced the results of preclinical in vivo research demonstrating the ability of AR-13324 to reduce episcleral venous pressure, or EVP, in the eye. AR-13324 previously has been shown to lower intraocular pressure, or IOP, by increasing fluid outflow through the trabecular pathway, the eye's primary drain, and by reducing the production of fluid in the eye. The present study affirmed the hypothesis that AR-13324 also can lower IOP through a third mechanism of action, the reduction of EVP. This may represent a breakthrough in the lowering of IOP in patients with glaucoma and ocular hypertension.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 12, 2015
14:18 EDTAERIAerie accelerated data read-out a positive, says Cantor
Subscribe for More Information
06:31 EDTAERIAerie Pharma accelerates of timeline for reporting results from Rhopressa trial
Aerie Pharmaceuticals announced the acceleration of the expected timeline for reporting efficacy results from the company’s 400-patient Phase 3 registration trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of RhopressaTM compared to timolol for the lowering of IOP. Timolol is the most widely used comparator in registration trials for lowering of IOP. In addition, there is a 12 month safety component to Rocket 2 and the Company is conducting a safety-only study in Canada, named “Rocket 3.” Pending the continued advancement of the RhopressaTM Phase 3 program and regulatory approvals, Aerie intends to commercialize RhopressaTM in North American markets and possibly Europe with its own sales force and will seek commercialization partners in other key territories, including Japan and possibly Europe. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use